UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009451
Receipt number R000011105
Scientific Title Ex vivo characteristic assessment of transcutaneous vaccine device by using human skin samples (age-comparison)
Date of disclosure of the study information 2012/12/01
Last modified on 2013/12/17 14:27:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Ex vivo characteristic assessment of transcutaneous vaccine device by using human skin samples (age-comparison)

Acronym

Ex vivo characteristic assessment of transcutaneous vaccine device by using human skin samples (age-comparison)

Scientific Title

Ex vivo characteristic assessment of transcutaneous vaccine device by using human skin samples (age-comparison)

Scientific Title:Acronym

Ex vivo characteristic assessment of transcutaneous vaccine device by using human skin samples (age-comparison)

Region

Japan


Condition

Condition

Flu

Classification by specialty

Infectious disease Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To study the antigen delivery of transcutaneous vaccine devices, self-degradating microneedles secreting fluorescence-labeled antigen will be applied onto human skin samples ex vivo. Cryosections of applied skin sample will be made to clarify the depth of antigen delivery. In addition, purified antigen presenting cells and keratinocytes from human skin samples will be used for in vitro assay to check the vaccine effects on immune cells.

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Antigen delivery mechanisms by microneedles will be elucidated in human skin by ex vivo studies.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

4

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Maneuver

Interventions/Control_1

Patients who will be performed skin surgery from December 2012 to March 2014 and who provide approximately 2 square meter surplus skin once
age: 5-15y.o.

Interventions/Control_2

Patients who will be performed skin surgery from December 2012 to March 2014 and who provide approximately 2 square meter surplus skin once
age: 16-40y.o.

Interventions/Control_3

Patients who will be performed skin surgery from December 2012 to March 2014 and who provide approximately 2 square meter surplus skin once
age:41-65y.o.

Interventions/Control_4

Patients who will be performed skin surgery from December 2012 to March 2014 and who provide approximately 2 square meter surplus skin once
age:>65y.o.

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

5 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patient who agreed informed consent to provide surplus skin during skin surgery

Key exclusion criteria

Patient who disagreed informed consent to provide surplus skin during skin surgery

Target sample size

12


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroaki Azukizawa

Organization

Osaka University, Graduate School of Medicine

Division name

Department of Dermatology

Zip code


Address

2-2, Yamadaoka, Suita, 565-0871 JAPAN

TEL

06-6879-3031

Email

azukizaw@derma.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroaki Azukizawa

Organization

Osaka University,Graduate School of Medicine

Division name

Department of Dermatology

Zip code


Address

2-2,Yamadaoka, Suita, 565-0871 JAPAN

TEL

06-6879-3031

Homepage URL


Email

azukizaw@derma.med.osaka-u.ac.jp


Sponsor or person

Institute

Osaka University, Graduate School of Medicine
Department of Dermatology

Institute

Department

Personal name



Funding Source

Organization

National Institute of Biochemical Innovation

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2012 Year 12 Month 01 Day

Date of IRB


Anticipated trial start date

2012 Year 12 Month 03 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 12 Month 01 Day

Last modified on

2013 Year 12 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011105


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name